Nanjing Legend Biotech Co.

This early-stage trial is testing a new treatment called LUCAR-G79D for people with lupus or inflammatory myopathies that haven't responded to standard therapies. The treatment involves giving patients specially engineered immune cells to help control their disease. The study is …

This study tests a new cell therapy called LCAR-F33S in 35 people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to attack the cancer. The main goals are to check safet…

This early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…